Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agree. Rally for four days is due for correction. Hopefully it can provide another opportunities for us to accumulate. GLTA!
Any idea why the Weekly Average Cost /Rx is dropping since week 34? Does this have anything to do with cost subsidy to patients by Sanofi? And what implication does this have to the future sales?
Share price dropped and hit new 52 week low with low volume is not a good sign to me. I expect a deep dive in the near trading days and thus have lowered my standby buy order from $2.86 to $2.55 (but for small quantity only if capitulation is not seen).
This is a very interesting perspective which I think has good reasoning to explain which the launch is controlled and slow. Good observation.
Since Oct 5, we have seen lower high and lower low, including today. Selling pressure is not high but buying power is also weak. All waiting for the presentation today in Las Vegas.
I do not understand what holds Edstrom back from talking. Pheffer seems to have been acting more like the CEO of the Company now-a-days. Why?
I'd like to know how Mr. Mann, who is the Executive Chairman to help the company in business matters, including those relating to development and financing of MannKind's future therapies.
Today IBB has dropped over 5% and MNKD is taking strong stand at $3.15 level (dropped by 1.25% only). Very interesting.
And again, nothing new and offers no insight at all, imo.
Does Your Child Dislike Shots? Looking Into Afrezza for Children
10/5/15 - TRIAL WATCH
Welcome to trial watch, where we keep an eye on the latest and greatest trials going on in the field of diabetes. Here, you can learn about new therapies and devices currently under study, and learn more about participating in these trials. Trial participants can get early access to new treatments, receive care at clinical trial centers, and are usually compensated for their time. You can read more about clinical trials at the “Center Watch” volunteer page or the ClinicalTrials.Gov information page.
Twitter Summary: Trial assesses the safety of inhaled rapid-acting insulin Afrezza for pediatric patients – enrolling now in CO + FL.
Clinical Trial Identifier: NCT02527265
Trial name: Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
Diabetes type: Type 1 diabetes
What it’s testing: This trial will assess the safety, pharmacokinetics (how a drug is metabolized by the body), and ability to titrate Afrezza (rapid-acting inhaled insulin) in children ages 4 to 17 years with type 1 diabetes.
Trial participants will initially receive a single dose at breakfast and have several blood draws for four hours to assess pharmacokinetics. They will subsequently receive an individualized dose of Afrezza at each meal (breakfast, lunch and dinner) for 30 days, with an optional extension of up to a year. All participants will receive injections of basal long acting insulin at bedtime each day.
What the trial is measuring: This safety study is focused on adverse events, hypoglycemia, and other critical safety outcomes in kids. More details here.
Why is this new/important: Afrezza was approved in 2014 in adults, and this study could help bring it to younger patients. We believe Afrezza would be particularly useful for children who are averse to needles and injections.
Trial Length: Six to eight weeks (from initial screening to the last follow-up visit), with optional extension up to a year for those who respond well to the Afrezza + basal insulin therapy.
Trial Location: The trial is currently recruiting in Aurora, Colorado and Gainesville, Florida.
Do you qualify?
4 - 17 years old
Type 1 diabetes and used insulin for at least one year
A1c of 7%-10%
Administering insulin via multiple daily injections (MDI) for at least 6 weeks prior to study
If on a pump, willing to convert to MDI for duration of trial participation
Basal insulin once daily in the evening
Individuals who answer “yes” to any of the following questions are not eligible for this study:
Do you have a body mass index (BMI) below the 25th or above the 95th percentile for age and gender according to CDC growth charts? (Calculate your BMI percentile here)
Have you ever been diagnosed with asthma?
Do you have an allergy or hypersensitivity to Afrezza?
For a full list of inclusion and exclusion criteria see here.
Source: http://diatribe.org/does-your-child-dislike-shots-looking-afrezza-children
Yes, I plan to start buying more at $2.86 & below. Subject to capitulation, I will buy as many shares as I can.
I have doubt there is any plan to kill the shorts at all. Management has been busy enough to deal with their own issues. Share price of the stock apparently is not the prime concern as note conversion due day is gone. The Company has just no time to care about things outside their control and beyond their capability. Thus priority is to stay focus on what they have been good at and not to be disturbed by noises.
To be fair to say, I think AF has his point whether or not we want to agree. It seems to me the Management has been lost in the mist dealing with financial matters waiting for Al to be the savior. I am not ready to load the truck currently as the cloud is still around and not light is seen at the end of the tunnel yet.
Disclosure: Maintain a small long position.
Trend, please provide a link and let us know which court has been accepted a submission for bankruptcy or will hold a section for bankruptcy declaration?
I believe King meant some of the data interpreted here may be biased.
Shifted a Global Project Manager from Toujeo onto Afrezza?
Based on the info you provided, I think NOT. Christine was the Project Officer, Toujeo (not a Global Project Manager, Toujeo) prior to being promoted to become a Global Project Manager, Afrezza.
Do correct me if my understanding is incorrect.
Kevin, could you repost your YMB thread in relation to the topic "What Manufacturing Update/Add On Did The FDA On 9/16/15 For Afrezza & Will It Generate a Milestone Payment from Sanofi.." It has been cancelled.
MannKind Cuts Its Headcount, But Will It Matter?
MannKind is laying-off workers to reduce expenses, but without sales growth these cuts may not be enough.
MannKind (NASDAQ:MNKD) continues to cut its expenses in response to a slower-than-hoped ramp up in sales for its inhalable insulin Afrezza; however, the pace of cuts may not be steep enough to matter if sales don't begin to materialize soon.
Troubling launch
Leading up to its launch, expectations were sky-high for MannKind's Afrezza.
Afrezza, which is taken via a small inhaler prior to mealtime, offers an alternative to short-lasting insulin injections that led many people to conclude patients would flock to it once it became available this past February.
However, sales reported by its marketing partner Sanofi have been lackluster. In the first quarter, Sanofi reports just 1.1 million euros in Afrezza sales, and in the second quarter, Afrezza sales were about 2.2 million euros.
Bloated business
The anemic Afrezza sales have led to MannKind playing defense in order to protect the cash it received from Sanofi when Sanofi signed on to market Afrezza last year.
MannKind's latest lay-off comes on top of two prior lay-offs earlier in the year and while the number of people let go hasn't been reported by the company, seemingly untenable losses suggest that it's not a stretch to think that more employees could lose their jobs if sales don't pick up.
Despite cost savings programs shaving tens of millions of dollars in quarterly expenses in the past year, MannKind's operating expenses of $24.1 million still led to a loss of $28.9 million in the second quarter alone.
Financially troubling
Execution missteps in the company's bid to win FDA approval led to unexpected trial costs and spending associated with management's overly enthusiastic sales projections have saddled MannKind with a troubling balance sheet.
Ultimately, without a pick-up in sales, MannKind's $107 million in cash on the books may not be enough to make good on its swelling liabilities.
Removing the $170 million in deferred payments tied to its collaboration with Sanofi that, for accounting reasons, shows up under short-term liabilities, MannKind's total liabilities still total nearly $300 million, including about $170 million that is categorized as current.
This means that MannKind's current ratio, a quick-and-dirty calculation that shows how able a company is to make good on its short term obligations, is just 0.43, which is down from 0.66 earlier this year.
Can MannKind turn a corner?
Investors that remain optimistic over MannKind's future believe that sales should increase once more insurers ink favorable deals with the company that result in Afrezza getting placed on drug formularies.
Appearing on those formularies could reduce the burden on doctors and patients hoping to get approved for Afrezza reimbursement, in turn leading to prescription growth.
If so, then the next couple quarters will be critical. Typically, it can take six to nine months for a review that could result in permanent placement on a formulary, so those decisions are happening soon, if not already.
Looking ahead
A pickup in sales is critical to MannKind's survival given that it gave up 65% of the rights to Afrezza's profit (or loss) as part of its licensing deal with Sanofi. Also, MannKind's product losses on Afrezza are running at about $12 million per quarter and MannKind has been covering its share of those losses by borrowing the money from Sanofi. If Afrezza becomes profitable, MannKind will need to pay Sanofi back before any money tied to Afrezza before it can reward investors. If MannKind can't pay back Sanofi, then Sanofi can take over MannKind's pledged assets, which in turn could significantly impact the company.
"In the event of certain future defaults under the Sanofi Loan facility agreement for which the Company is not able to obtain waivers, the lender under the Sanofi Loan Facility may accelerate all of the Company's repayment obligations, and take control of the Company's pledged assets, potentially requiring the Company to renegotiate the terms of its indebtedness on terms less favorable to the Company, or to immediately cease operations" -- MannKind's second quarter 10-Q.
If sales don't pick-up, then its unclear to me what the future will hold for the company. Sanofi has an option to exit its relationship with MannKind as early as next year, and although MannKind has said it's exploring the use of its inhalable technology for other medicine, it could be a long wait before any additional products make it to market. For those reasons, MannKind is far too risky of a bet for investors to own.
http://www.fool.com/investing/general/2015/10/01/mannkind-cuts-its-headcount-but-will-it-matter.aspx?source=eogyholnk0000001&utm_source=yahoo&utm_medium=feed&utm_campaign=article
MNKD really needs to be less dependent on Afrezza sales and allocates more efforts in other TS applications (collaboration with other BP) to keep its head above water, imho.
I hope the Company can provide more details of the layoffs in terms of number, level & function of those affected of each site.
MannKind engages in third round of layoffs in Danbury By Dirk Perrefort | September 30, 2015
MannKind (Nasdaq: MNKD), a drug manufacturer in Danbury, has laid off workers as part of a reorganization effort amid slower-than-expected revenue from the company’s main product.
The company’s stock, meanwhile, hit a 52 week low earlier this week after trading at around $3 per share.
CFO Matt Pfeffer confirmed this week that an undisclosed number of layoffs have occurred at the pharmaceutical company - the third round of job cuts this year - as part of an ongoing effort of “right-sizing the company to reflect anticipated demand and operational needs.”
“These reductions affected all of our sites, both here on the east coast as well as California, and affected all levels of management in the company,” Pfeffer told The News-Times this week.
He said the reorganization was aimed at providing a more efficient operating structure after sales of Afrezza, the inhaled form of insulin that is MannKind’s primary drug, were “different” than anticipated.
Sales of Afrezza—which was approved by the U.S. Food and Drug Administration last year and hit the market in February— so far have been lackluster, with marketing partner Sanofi reporting total sales of about $5.5 million as of June 30.
Despite the lower-than-expected sales, the company announced in August that it was tripling its production of Afrezza at the Danbury plant.
“The company is very different today than it was a year ago or two years ago and we have very different needs,” Pfeffer told The News-Times in a statement earlier this week. “The projected sales curve for our lead product is also different than we anticipated. All these things, taken together, cause us to continually re-evaluate our needs and our organizational structure to make it optimal from an efficiency and cost standpoint. This is just good business practice.”
Pfeffer noted that the company has closed its facility in Paramus, N.J. and moved certain functions from its Valencia, California, headquarters to the Danbury facility, which is located on Casper Street near the city’s downtown. A number of the local employees who have been laid off, he said, were short- term transfers from the New Jersey facility. Others laid off at the California facility, he said, are being replaced with new hires at the Danbury plant.
The company’s stock, which hit a low of $3 on Tuesday, bounced back and closed up 9 cents at $3.21 on Wednesday.
http://m.newstimes.com/business/article/MannKind-engages-in-third-round-of-layoffs-in-6541355.php
Why Sanofi's marketing strategy brilliant - by cfield23
This is meant to be long-winded and comprehensive.
Let me start this off with a few disclosures:
• I am long MNKD for about a year and have done countless hours of due diligence before I decided to invest.
• I am a long-term focused investor. I make few trades, so it takes a long time for me to pick a company. I like to set & forget and to buy the dip.
• I have no idea what's going to happen from day to day, and quite frankly, I don't care. I'm confident in the long-term prospects
• My career is in marketing -- specifically, lead generation/advertising.
• Yes, I am a newbie poster here, but I've lurked for a while. You can find me on stocktwits and twitter under the same username.
Coming from a marketing/advertising standpoint, this roll-out is great thus far (for Afrezza's success -- not short term stock traders). I believe Sanofi's strategy for rolling out Afrezza follows a simple, structured plan.
I believe the 5 steps are:
1. Completion of the CLAMP Study (https://clinicaltrials.gov/ct2/show/NCT02470637)
2. Apply for a new, better label (allows them to make bold advertising claims)
3. Use the new label/clamp study results to gain Tier 2 insurance coverage
4. Gain approval in other countries
5. Once insurance mostly covers Afrezza, Sanofi will hire more sales reps and begin a "full-on" DTC campaign.
Sanofi’s Current (9/29/15) Advertising
Advertising is meant to spread awareness about one’s product. Its eventual goal is to convert the user from an impression (showing of the ad) into a sale (or prescription, in this case).
Based on what I have seen so far, Sanofi is definitely ramping up their advertising efforts. They are choosing the channels that are cheapest first, and that provide a level of awareness. It started out with paid search ads on branded terms like “insulin human” or “Afrezza”. These are cheapest because they own these terms, making it harder for others to “outbid” for the top ad spot. Since then, we’ve seen them start to bid on other diabetes terms as well as begin their display advertising though banners on several sites. Finally, they have appeared in Time Magazine multiple times, as well as Good Housekeeping and others!
The purpose of this is to pique the interest of the viewer, but NOT to make them jump up and call their doctor. It is solely to make them more generally aware of the product. As time goes on and they see it more and more places, the viewer will then say “hmm… I’ve seen it here, here, and here… maybe I should check it out?”
This is where timing is everything…
Imagine you’ve seen a TV ad for Afrezza and you visit your doctor (before the above step 3 is complete). Consider the following scenarios and how they would present barriers to prescriptions/renewals.
• What if your doctor hasn’t heard of Afrezza yet? There are many drugs and it takes time to learn.
• What if your doctor does some research and isn’t impressed by the FDA trial results? Will he/she prescribe?
• Suppose your doctor has heard of Afrezza. Suppose he prescribes! What happens if your insurance doesn’t cover it?
• What happens when the samples run out and it’s too expensive to continue
All of these scenarios can negatively affect your opinion on whether to continue/get started. If Sanofi is able to complete the 3rd step (above) before your first real impression (with the doctor) happens, the chances of success are much higher.
I believe Sanofi currently spending minimal $'s on advertising right now because the patient's experience isn't greatest yet (high cost, insurance claims, pre-authorizations, tests, etc.), and the claims they’re legally allowed to make aren’t that impressive yet.
Advertising Failure Case Study: Exubera
One of the reasons Exubera failed was due to it's huge ($370M in ads) overhead cost. It literally put a time limit to the success because scripts HAD to increase in order to justify continual spending. Because scripts didn't increase quickly, they had to make a rather quick/abrupt decision about keeping the drug.
Now it’s not quite fair to compare Afrezza and Exubera and attribute advertising as the sole reason for failure. The actual Exubera insulin was average to inferior as compared with the RAA’s available at the time. The delivery device was also the size of a new 3 pack of tennis balls! These most certainly didn’t help the success.
It failed because while it was better to inhale than to inject, it was much harder to get the insulin and it was less effective. The hassles outweighed the benefits by a wide margin. Plus, Pfizer spent so much up front that they lost all possible response agility. They weren’t able to listen to the problems and fix them. They were bleeding money.
"Yet Exubera cost Pfizer $775 million to manufacture and promote this year, according to an estimate by a drug-industry analyst at Credit Suisse Group."
Quote Source: www.wsj.com/articles/SB119284606824265824
"Pfizer has spent in the region of USD 370m so far in 2007 to promote Exubera. Activities have included the sending of special diabetes educators to doctors to teach them how to use the new device, as well as DTC advertising investment. In comparison, say Credit Swiss analysts, the promotion of Pfizer's new cancer drug Sutent (imatinib), only cost Pfizer USD 200m."
Quote Source: www.pmlive.com/pharma_news/pfizer_scraps_exubera_9168?SQ_DESIGN_NAME=2&
Afrezza: Monomer vs. Hexamer & a1c’s.
Here’s a simplistic explanation of the why Afrezza’s PK profile is important:
Afrezza is a monomer. That means there’s only one molecule for the body to break down. Since that molecule is insulin and absorbable in the blood stream, it happens immediately, peaking in 12-15 minutes.
A hexamer (traditional RAA structure) means that there are six insulin molecules bonded together by zinc. Your body has to break down the zinc before it’s able to access the insulin. And repeat, repeat, repeat, repeat, repeat. This is why diabetics take their mealtime (prandial) insulin about 40 minutes before they begin to eat. They must plan ahead as to when the insulin will be absorbing in their system (based on when the body will have broken down the zinc). It is also why sometimes after a meal, they have a hypoglycemic event (the body hasn’t finished breaking down the zinc to get to the insulin). It’s a difficult process and very hard to control.
Here’s a graph to help explain: 1.bp.blogspot.com/_7SznemQYk7M/TOvPyBmkGHI/AAAAAAAAAC0/eVD8nkJATdc/s1600/Afrezza+Insulin+Resonse.JPG
Notice that if you take Afrezza too early, you miss out on the peak.
What does this mean for a1c values?
Your HbA1C value is the most important value if you’re a diabetic. Simply put, it is the average of glucose in your blood over a period of time. Usually it’s taken every 90 days at a doctor’s checkup. If the value is high over the long term, you run into unfortunate effects like loss of limbs and blindness later on. If your value is normal over the long term, your body functions normally.
Just as with anything else, an average of a1c takes outliers into account. These mealtime spikes raise the average over the long period of time. The more you can do to limit the number of spikes, or the height of each spike, the lower your average and the less likely you are to have later complications.
Because Afrezza peaks in 12-15 minutes, it’s able to handle the spikes in glucose during a meal. It’s able to significantly lower the height IF TAKEN PROPERLY right as you start to eat. Lower “highs” means a lower average and a reduction of a1c – and less later in life complications.
Because the trials had participants take Afrezza at the time they would’ve taken hexameric RAA’s, the results showed only modest effectiveness. This is why the CLAMP study is needed. I am confident that if taken correctly, Afrezza’s results will be astounding.
What would a TV ad say? Today vs. Tomorrow.
Today, because of the label restrictions, a TV ad would only be able to tout the same thing Exubera touted: Inhaled vs. Injected. Do we really want to go down the same path?
If this is the only benefit to Afrezza (remember, think in a vacuum, as we can only advertise what’s allowed), then it’s easy to see why people think its niche. I, too, believe that if Afrezza’s only benefit were that it’s inhaled, then it wouldn’t be likely to gain significant market traction. If I believed that, though, I wouldn’t have invested.
However, after the CLAMP study is completed, if the results show what we’re expecting (much fewer hypo events, large reductions in HbA1C values, etc), then the label will most certainly change for the better – allowing Sanofi to make bold, gripping claims.
A TV commercial that can make claims as bold as “significant a1c reduction” & “much less risk of going hypoglycemic” will most certainly send the patients to the doctors, as well as force doctors to do their own due diligence.
Conclusion
During the FDA trials, Afrezza patients didn’t take Afrezza at the start of the meal, but rather around when they would’ve taken their RAA. As we know, a monomer is absorbed quicker (reference the chart above if needed, again) and thus begins exiting the body quicker, too. This led to rather average results and a tough label.
Once the label is improved, insurance coverage will be easier to gain. Less complications from diabetes (because of lower a1c’s) means less insurance claims and more profit, so insurance companies will undoubtedly cover it.
Once insurance coverage and the label is improved, TV ads will start (and not a second sooner). This will ensure that the dollars spent on advertising is used as efficiently as possible.
I truly believe that the “inhaled” benefit is, and should be marketed as, secondary. People need to learn that the Afrezza insulin is the best at controlling sugars. It is the only insulin that mimics the human pancreas’s insulin. Once people see it that way (by legal label claims), they’ll be even more thrilled that they don’t have to inject it either.
While the short term share price can be frustrating, you can most assuredly take solace in the fact that Sanofi isn’t spending too much to NEED results NOW. They can afford to wait until everything is aligned. In fact, that’s exactly what they’re doing, and what they should be doing.
Thank you for reading!
Source from: http://mnkd.proboards.com/thread/3616/why-sanofis-marketing-strategy-brillian
Would savvy pharma investors (or institutional investors) tell you what they are currently accumulating? I guess not until they have bought more than enough shares and issue coverage after pps has gone up quite a bit.
It could likely be the selling and buying between groups of shorts who intentionally drive the pps down at close to create panic selling or trigger stop loss.
I will not be surprised if the pps be lowered to below $3.00. My own re-entry PT is below $2.90. I will be buying all I can if the price is below $2.67.
Disclosure: long with average of $3.89.
MNKD gets what it takes to shoot the moon?!
http://whatis.techtarget.com/definition/moonshot
It's getting funny posting here. Always get deleted.
Afrezza is excluded from Sierra Health & Life (A United Healthcare Company) per 3-Tier Drug Benefit Guide dated 9/01/2015. Under Exclusions (drug section 14A). Generic name: insulin regular (human) inhalation powder.
www.healthplanofnevada.com/documents/3_tier_pdl.pdf
And the drug is also to be excluded by United Healthcare effective from Jan 1, 2016
http://www.uhc.com/content/dam/uhcdotcom/en/Pharmacy/PDFs/Traditional4TierPlans.pdf
Just wonder how many doctors accept United Healthcare or Sierra Health & Life?
Probably they have a hidden Team C to carry out Plan C (Contingency) as well.
MNKD and PJC are both bad?
In short, MNKD needs more solid sales and PJC needs more quality analysts!
MannKind Corporation is having a rough time in the market today as investors take in the news of a recent downgrade by Piper Jaffray. Today, we’ll take a look at what Piper Jaffray has to say about the stock, how MNKD reacted to the news, and what we can expect to see moving forward.
What Piper Jaffray Has To Say About MNKD
According to Street Insider, Piper Jaffray downgraded MannKind from a “Neutral” rating to an “Underweight” rating dropping their target price on the stock from $4.00 to $1.50. Here’s what analyst Joshua Schimmer had to say about MNKD…
“IMS scripts for Afrezza have been lackluster to say the least, so we spoke with five primary care and endocrinology specialists with high volumes of diabetes patients to gauge their experience with and outlook for the product. Unfortunately it sounds to us that while awareness is high and some patient blogs on the internet describe some very exciting and differentiated results, Afrezza is being viewed as a very niche product. Physicians envision growing use in their practices, but not dramatically so. We believe MNKD has vastly over-estimated the commercial potential for the drug and are lowering our penetration estimates. Even our revised assumptions may be too aggressive so our discount rate is increasing from 10.5% to 11%. Our new PT is $1.50/share, which is roughly 60% down from current levels.”
How MannKind Reacted To The News
As one would expect, MannKind is having an absolutely horrible day in the market today following the analyst’s downgrade. Currently (11:21), the stock is trading at $3.76 per share after a loss of 7.49%.
MNKD Isn’t A Bad Stock In My Opinion
I know I’m going to catch hell for this one in comments and in social media, but I don’t mind. The simple fact is that, in my opinion, MannKind is a strong stock for the long run. Here’s why…
Piper Jaffray Assessment Is Invalid – Piper Jaffray talked to only 5 doctors! Anyone that works in a statistics-based position will tell you that you need at least 30 data points in order to come up with reliable statistics. The simple fact is that there are far too many variables to get realistic figures from only 5 data points. Also, we know nothing of the physicians and endocrinology experts; I’m not sure this was a blind survey. All in all, unless Piper Jaffray interviews at lest 30 doctors in a blind setting, I wouldn’t be willing to take their word.
Afrezza Has Had A Slow Start, But Wait! – There’s no doubt that Afrezza has had a slow start; investors have a right to be upset about that. However, every insulin dependent diabetic I’ve spoken to said they would rather inhale insulin than take a shot. It’s a no-brainer. The only problem is that consumer awareness is lacking. However, I’m not sure that will be the case for much longer. As consumers become aware, sales will rise. It’s also important to note that the lackluster sales we’ve seen are, in part, because of insurance coverage. After all, without insurance coverage, companies have a hard time selling prescription medications. However, recent data shows that about 80% of insurers plan on covering Afrezza in one way or another which is likely to give sales a big boost!
Afrezza Isn’t The Only Product – Yes, Afrezza is MannKind’s only approved product, but it’s not the only thing MNKD has in the pipeline. Too often, analysts are forgetting that MannKind is working on several different medications, one of which is a pain relief product that looks incredibly promising. So, even if you have absolutely no faith in Afrezza, there is still plenty to be excited about!
What We Can Expect To See Moving Forward
First and foremost, I think that today’s declines are a gross overreaction. Therefore, we can expect to see gains tomorrow as the stock corrects. Beyond that MNKD is likely to run into more turbulence in the near term (2 to 3 months) thanks to Piper Jaffray and other bearish opinions combined with heavy short selling on the stock. However, I think that the year 2016 will bring gains that will take the bears by surprise.
http://cnafinance.com/mannkind-mnkd-stock-falls-on-piper-jaffray-downgrade/6011
A lot of banks have been a failure in the past and will also be in the future.
Do not reply on what banks tell you. Most of their top management works for their own vision and year end bonus, not yours.
Banks are your friend only when you don't need them.
I will not be surprised if dilution takes place at $11.00.
But I think a Buy and Hold strategy for MNKD is very risky.
This is correct from a trader's perspective. Traders do not invest in a company but hope to maximize their profits in a short term like a few days or even during trading session. Some of them are not willing to take a position longer than what they can afford to. I see no problems with that.
Agree. I have set my buying order at $2.86 which will probably get filled within this week.
Thanks!
"This was a solid board between bulls and bears, but has now gotten to be a bear board, so no bulls need apply." --- Very good observation.
It seems a bit strange to me that the trading volume today is not very substantial.
Sounds like you agree that Afrezza is a replacement of injected insulins. I do not think this is anything complicated here. In fact, Afreeza is prandial insulin. I hope patients do not misuse the drug.
You just do it anyway -- because you have no viable option available?
Trend, I never convince you or anyone here what to believe. It was just a piece of information I provided for you as reference. It is upto you or other readers to decide if it should be part of the DD.
If you did track my buy sell record, you would not be surprised I did what I did (based on chart).
Last Friday I sold 2/3 of what I accumulated at ave. @ $4.10 waiting for re-entry point towards mid- Sept. I.e. one month correction is what I am expecting.
Sure. These companies have stories to tell and investment bankers to sell. I guess ELTP needs to establish firm relationship with IB to sell their stories. Just saying.